ZTE
ZTE, one of the top global handset manufacturers, today announces one of the first few pre-loaded Google Now Launcher smartphones among non-Nexus and non-Google Play Experience devices worldwide to offer improved user experience and better value. The ZTE Blade Vec 4G smartphone with Google Now Launcher incorporates the Qualcomm® Snapdragon™ 400 processor and furthers ZTE’s strong relationship with Google and Qualcomm Technologies in growing the LTE market.
ZTE has worked closely with Google to pre-load Google Now Launcher onto several ZTE devices. The ZTE’s Blade Vec 4G smartphone on Android 4.4 and Snapdragon 400 processor with integrated multi-mode 3G/4G LTE is designed to deliver a better user experience that is supported by 3 modes (4G LTE-FDD, 3G UMGS/TD-SCDMA) and 9 radio frequency bands.
The ZTE Blade Vec 4G smartphone along with one other ZTE premium device will be officially presented at a ZTE press conference held in Hong Kong on July 24, 2014. ZTE has launched the Blade Vec 4G and other premium devices in Europe and in China, and now will make them available in Hong Kong with the added benefits of Google Now Launcher pre-loaded.
ZTE plans to pre-load Google Now Launcher on all Android 4.4 and above smartphones that have Google Mobile Services and Google Play enabled. Having Google Now Launcher pre-loaded onto the ZTE Blade Vec 4G, the new device becomes the first systemic terminal voice control solution in the industry. Mr. Zeng Xuezhong, CEO of ZTE Mobile Devices, and Executive Vice President of ZTE Corporation, commented, “ZTE’s strong relationship with Google and Qualcomm Technologies is in line with our focus on developing affordable premium devices that has rich voice control function as well as multimedia solutions. ZTE is continuing to push the boundaries and brings its customers the very latest experience that mobile technology can offer.”
On the ZTE Blade Vec 4G smartphone, Google Now Launcher is complimentary to ZTE flagship devices’ voice recognition and control function. ZTE Blade Vec 4G strongly features voice command functionality, including phone unlocking, dialing / answering calls, playing music, navigational controls, taking photos, etc.
Visually appealing UI
The Google Now Launcher UI lets users add as many home screens as they like, and helps them quickly get to their favorite apps. Another feature is the method for user to add widgets. To personalize and embellish ones smartphone, a user can select any images stored in the device or in the cloud or adjust the position of the image and preview before saving the setting.
Quick and easy access to Google Now
Google Now gives users just the right information at just the right time. For example, if you've booked a flight on selected airlines Google Now can give you your boarding pass, or tell you if the flight is delayed.
Free hands with a hotword
Ok Google allows hand free voice command triggered by just saying “Ok Google” at standby mode. Tell the phone what to do, not only limited to search query, text a message, get directions, or play a song, but even setting reminders and alarms, opening apps. Google Now Launcher supports multiple languages without presetting language in phone. Google Now Launcher gives users a clean and simple user interface, and keeps Google Now and search just a swipe or a tap away.
Key benefits
•A visually appealing UI.
•Quick and easy access to Google Now.
•Fast and snappy.
•The “Ok Google” hotword for opening quickly accessing Google Search
Contact:
ZTE Corporation
Margrete Ma, +86 755 26775207
ma.gaili@zte.com.cn
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 11:15:00 CEST | Press release
− Sustained Benefit of Vutrisiran Across Mortality, Cardiovascular Events, Quality of Life and Cardiac Biomarkers Observed Through Up to 48 Months, Including 12 Months from the Ongoing Open-Label Extension, Reinforce Potential as First-Line Treatment for ATTR-CM –− Vutrisiran, which Delivers Rapid Knockdown of Transthyretin, Reduced the Risk of Composite of All-Cause Mortality or First Cardiovascular Event by 37% in the Overall Population and 42% in the Monotherapy Group During the Same Period – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Card
WETEX Opens Broad Investment Horizons for International Companies31.8.2025 08:30:00 CEST | Press release
DEWA will organise the exhibition from 30 September to 2 October 2025 Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial i
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release
Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t
Andersen Consulting styrker sine kompetencer inden for virksomhedstransformation med Fabric29.8.2025 17:01:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Fabric, der er et strategisk designfirma, der arbejder med organisationer for at integrere bæredygtighed, forsyningskæder og menneske-centreret innovation på tværs af kultur og drift. Fabric blev grundlagt i Japan i 2021 og arbejder sammen med virksomheder og globale brands om at skabe regenerative forretningsmodeller sammen samt bæredygtige brandstrategier og fremtidssikrede produkter. Ved hjælp af strategiske designmetoder og designfilosofi skaber virksomheden indsigtsbaseret transformation på tværs af forsyningskæder, brand og HR. Fabric er kendt for sin systemtænkning og sit engagement i social og miljømæssig bæredygtighed og fremmer desuden digitale transformationsinitiativer, der integrerer bæredygtighed, humankapital og AI. "Fabric er skabt for at hjælpe virksomheder med at blomstre gennem regenerative relationer til mennesker, samfund og forbundne, levende systemer," sagde James Hollow, der er grundlægger a
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum